Novavax 2026 Conference Call Summary Company Overview - **Company**: Novavax (NasdaqGS: NVAX) - **Focus**: Transition from COVID vaccine development to innovative partnerships and business development leveraging its Matrix-M adjuvant technology and nanoparticle technology [1][3] Core Strategies and Developments - **Pivot in Strategy**: Novavax has shifted from solely focusing on COVID vaccine development to a broader strategy involving partnerships and out-licensing its technology [3][4] - **Partnerships**: Recent deals with Sanofi in 2024 and Pfizer in January 2026 highlight the company's strategy to leverage its technology for multiple vaccine candidates [4][11] - **Research and Development**: The R&D team is focused on three key areas: data generation, innovation in adjuvants, and developing new assets using nanoparticle technology [5][6] Key Technologies - **Matrix-M Technology**: This adjuvant technology is central to Novavax's strategy, showing potential in both vaccine and immunotherapy applications, particularly in oncology [9][24] - **Pipeline Candidates**: Novavax is developing vaccines for Clostridioides difficile, Varicella-Zoster Virus (VZV), and Respiratory Syncytial Virus (RSV), with potential clinical trials starting as early as 2027 [6][30] Financial Performance and Projections - **Financial Health**: The company has significantly reduced R&D and SG&A expenses by over $1 billion and current liabilities by $2 billion, positioning itself for potential non-GAAP profitability by 2028 [56][57] - **Revenue Streams**: The Pfizer deal includes a $30 million upfront payment and potential milestones of up to $500 million, along with royalties that could yield significant long-term revenue [20][21] Market Potential - **Vaccine Market Growth**: The global vaccine market is projected to exceed $60 billion by 2032, presenting substantial opportunities for Novavax's technology [27] - **Unlocking Value**: The technology's ability to enhance immune responses and reduce costs of goods is appealing to potential partners, particularly those facing challenges in their own pipelines [25][28] Upcoming Catalysts - **Partnership Announcements**: Continued execution of the partnership strategy with potential new deals expected [11][22] - **Advancements from Existing Partnerships**: Monitoring developments from partners like Sanofi and Pfizer, particularly regarding the launch of Nuvaxovid and combination vaccine programs [22][23] - **Pipeline Progress**: Data and innovations from Novavax's own R&D efforts will be critical to future growth [24] Intellectual Property and Competitive Position - **Patent Protection**: Novavax has existing or pending patent applications for Matrix-M that extend into the 2040s, providing a competitive edge in the vaccine market [43][51] Conclusion - **Future Outlook**: Novavax is optimistic about its position in the biotech landscape, focusing on value creation through partnerships and innovative technology, with a strong emphasis on collaboration and humility in its corporate culture [68]

Novavax FY Conference Summary Company Overview - **Company**: Novavax (NasdaqGS: NVAX) - **Event**: FY Conference held on March 03, 2026 Key Points Strategic Shift - Novavax has successfully pivoted from being solely focused on COVID-19 to a broader strategy that includes out-licensing its technology and expanding its R&D efforts [4][5] - The company aims to generate data to support its technology and expand the utility of its Matrix-M adjuvant platform, including new formulations like dry powder [4][5] Partnerships and Collaborations - Novavax has established partnerships with major pharmaceutical companies, including Sanofi and Pfizer, to utilize its Matrix technology in their vaccine development [5][6] - The company is seeing increased interest from potential partners, indicating a strong market demand for its technology [6] Upcoming Milestones - Key milestones for 2026 include feedback from Sanofi on clinical trials for combination vaccines and initial steps from Pfizer regarding their selected area for Matrix-M exploration [7][9] - New partnership announcements and data from Novavax's pipeline are also anticipated [9] Market Positioning - Nuvaxovid is well-positioned in the U.S. COVID vaccine market, with Sanofi leading commercialization efforts. The vaccine's tolerability profile is highlighted as a significant advantage [10][11] - Sanofi's proprietary distribution network and their methodical approach to building market share are expected to enhance Nuvaxovid's performance [12] Financial Outlook - Novavax has a strong financial position with a cash runway expected to last into 2028, supported by non-dilutive cash from partnerships and credit facilities [30] - The company aims for non-GAAP profitability by 2028, with potential contributions from milestones and royalties from vaccine sales [31][32] R&D Focus - Novavax is developing a portfolio of new adjuvants to enhance immune responses for difficult-to-treat diseases, including oncology [20][22] - The company is exploring the use of Matrix-M in oncology, emphasizing partnerships rather than becoming an oncology company itself [22] C. difficile Vaccine Development - Novavax is working on a C. difficile vaccine, addressing a significant unmet medical need as there is currently no vaccine on the market [23][24] - Early preclinical data for the C. difficile vaccine is promising, with a focus on generating mucosal immunity and durable immune responses [25][28] Cost Management - The company has significantly reduced its SG&A and R&D expenses from approximately $1.7 billion to a target of $200 million or below by 2028 [33][34] - This lean infrastructure is designed to support multiple partnerships and revenue generation opportunities [34] Future Expectations - Novavax plans to continue building partnerships with various pharmaceutical companies, aiming for multiple revenue streams through royalties and milestones [34][35] - The company is optimistic about achieving its financial and strategic goals, with a focus on transparency in future announcements [35] Conclusion - Novavax is positioned for growth through strategic partnerships, a diversified pipeline, and a strong financial outlook, with a focus on addressing unmet medical needs and achieving profitability by 2028.

Core Insights - Novavax reported earnings of 11 cents per share in Q4 2025, significantly beating the Zacks Consensus Estimate of a loss of 66 cents, and improved from a loss of 51 cents in the same quarter last year [1][8] - Quarterly revenues reached $147.1 million, representing a 67% year-over-year increase, surpassing the Zacks Consensus Estimate of $78.4 million [1][8] Financial Performance - The company recorded $39.2 million in product sales, a decrease of 34% year over year, which included approximately $20 million from COVID-19 vaccine sales and $19 million from Matrix-M supply sales [4] - Licensing, royalties, and other revenues totaled $108 million, with $98 million recognized under the licensing agreement with Sanofi, marking a 67% increase year over year [5][8] - For the full year 2025, Novavax generated revenues of $1.1 billion, up 65% year over year, and reported earnings of $2.58 per share compared to a loss of $1.23 in the previous year [11] Cost Management - Research and development (R&D) expenses were $75.9 million, down 27% year over year, aided by cost reduction efforts, excluding $28 million of R&D reimbursement from Sanofi [9] - Selling, general, and administrative (SG&A) expenses decreased by 56% year over year to $34.1 million, primarily due to the transition of commercial activities to Sanofi [9] Cash Position - As of December 31, 2025, Novavax had $751 million in cash and cash equivalents, a slight decrease from $778 million in the previous quarter [10] Future Guidance - For 2026, Novavax expects adjusted revenues between $230 million and $270 million, excluding amounts receivable from Sanofi [12] - The company anticipates combined R&D and SG&A expenses for 2026 to be in the range of $380 million to $420 million, excluding expected R&D reimbursements from Sanofi [13] Recent Developments - Novavax entered a non-exclusive license agreement with Pfizer, receiving an upfront payment of $30 million and potential milestone payments up to $500 million [14] - The company signed multiple material transfer agreements for its Matrix-M adjuvant and is advancing its preclinical pipeline, with plans to start clinical studies on new vaccine candidates as early as next year [15]

Core Viewpoint - Novavax reported a significant turnaround in its financial performance for Q4 2025, with a notable increase in revenue and a return to profitability [2][3]. Financial Performance - Q4 earnings per share were $0.11, compared to a loss of $0.51 per share in the same period last year, marking a successful turnaround [2]. - Q4 revenue reached $147 million, representing a 67% year-over-year increase [2]. - The company exceeded its cost reduction targets for R&D and SG&A expenses in 2025 and is tightening future spending goals, projecting R&D and SG&A expenses of $325 million in 2026, $225 million in 2027, and $200 million or less in 2028 [2]. Management Commentary - The CEO highlighted significant strategic progress in 2025, including achieving key milestones under the Sanofi agreement and advancing R&D efforts through collaborations [3]. - The company anticipates a strong start in 2026, particularly with the recent agreement with Pfizer, and is looking forward to more potential partnerships to drive innovation and value creation [3]. Revenue Guidance - Novavax provided revenue guidance for 2026, expecting adjusted total revenue between $230 million and $270 million, while market expectations are at $381.22 million [4]. - The company forecasts Nuvaxovid product sales of $35 million to $45 million and adjusted supply sales of $40 million to $50 million, reflecting ongoing collaborations with partners like the Serum Institute [4]. Technical Analysis - The stock is currently trading 8.4% above its 20-day simple moving average (SMA) and 9.2% above its 100-day SMA, indicating short-term strength [5]. - Over the past 12 months, the stock has shown a significant upward trend, nearing its 52-week high [5]. - The relative strength index (RSI) is at 44.45, indicating a neutral position, with no immediate bullish or bearish pressure evident from MACD signals [5][6]. Key Support and Resistance Levels - Key resistance level is at $12.00, while key support level is at $10.50 [7]. - Analyst consensus holds a "hold" rating with an average target price of $32.23, with recent analyst actions including a buy rating from BTIG and a downgrade from Morgan Stanley [7][8].

Core Viewpoint - Novavax Inc. reported a significant improvement in its financial performance for the fourth quarter and full year of 2025, with shares rising following the announcement [1]. Financial Performance - The company reported fourth-quarter earnings of 11 cents, a notable recovery from a loss of 51 cents in the same quarter last year [2]. - Revenue for the fourth quarter reached $147 million, reflecting a 67% year-over-year increase [2]. Cost Management - Novavax exceeded its 2025 cost-cutting targets for both GAAP and Non-GAAP R&D and SG&A spending, and is tightening future expense goals [2]. - The company now anticipates Non-GAAP R&D and SG&A expenses of $325 million in 2026, $225 million in 2027, and $200 million or less in 2028 [3]. Management Commentary - The President and CEO of Novavax highlighted significant progress in corporate strategy, including achievements under the Sanofi agreement and advancements in R&D efforts [4]. Revenue Guidance - Novavax provided a revenue forecast for 2026, projecting adjusted total revenue between $230 million and $270 million, which is below the consensus estimate of $381.22 million [5]. - The company expects Nuvaxovid product sales to be between $35 million and $45 million, along with adjusted supply sales of $40 million to $50 million [5]. Technical Analysis - The stock is currently trading 8.4% above its 20-day simple moving average (SMA) and 9.2% above its 100-day SMA, indicating short-term strength [6]. - Over the past 12 months, shares have shown significant growth and are closer to their 52-week highs, reflecting a strong upward trend [6]. Momentum Indicators - The RSI is at 44.45, indicating neutral territory, suggesting the stock is neither overbought nor oversold [7]. - The absence of significant MACD crossovers indicates a stable trend without immediate bullish or bearish pressure [7]. Analyst Consensus - The stock carries a Hold Rating with an average price target of $32.23 [8]. - Recent analyst actions include a Buy rating from BTIG with a target of $19.00, while JP Morgan has an Underweight rating with a lowered target of $6.00 [8].

Financial Data and Key Metrics Changes - The company reported total revenue of $1.1 billion for the full year 2025, a 65% increase year-over-year, including $625 million from non-cash revenue recognition related to Nuvaxovid agreements [30][31] - For Q4 2025, total revenue was $147 million, reflecting a 67% increase compared to Q4 2024 [31][36] - Positive income was reported for both the full year and Q4 2025, indicating improved financial performance [31][38] - Combined R&D and SG&A expenses were reduced by 42% and 53% for Q4 and full year 2025, respectively, while maintaining partnership commitments [32][38] Business Line Data and Key Metrics Changes - Nuvaxovid product sales for Q4 2025 were $20 million, with additional supply sales of $19 million from Matrix-M adjuvant sales [36] - Sanofi's licensing, royalty, and other revenue for Q4 2025 was $98 million, driven by milestone achievements and R&D reimbursements [36] Market Data and Key Metrics Changes - The company noted significant market share gains for Nuvaxovid in Japan, with Takeda achieving over 12% market share [9] - Over 30 million doses of the R21 Matrix-M malaria vaccine have been distributed by Serum Institute [9] Company Strategy and Development Direction - The company has shifted from a singular focus on COVID to a broader strategy that includes partnerships and R&D, aiming for long-term value creation [7][8] - A new partnership with Pfizer for Matrix-M was announced, which could generate billions in revenue through milestones and royalties [8][9] - The company is exploring new formulations and applications for Matrix-M, including potential uses in oncology and hard-to-treat infectious diseases [11][19] Management's Comments on Operating Environment and Future Outlook - The management acknowledged uncertainties in the current macro and regulatory environment for vaccine companies but remains optimistic about the long-term need for vaccines [13] - The company anticipates significant growth opportunities in the vaccine and immunotherapeutic markets, projecting a potential market size exceeding $100 billion by the early 2030s [20][21] Other Important Information - The company ended 2025 with $857 million in cash and accounts receivable, with an additional $80 million in non-dilutive cash expected in Q1 2026 [32][33] - A new credit facility of $330 million was established to support ongoing operations and growth strategy [33] Q&A Session Summary Question: Update on Sanofi's vaccine business with new CEO - Management expressed confidence in the ongoing partnership with Sanofi, noting that interactions remain positive despite leadership changes [51] Question: Prioritization of early pipeline programs - The company is advancing multiple early-stage programs, including C. diff, VZV, and RSV, each at their own pace [54][55] Question: Potential for co-promotions in partnerships - The company is currently focused on partnerships rather than building a commercial framework but remains open to co-promotions if a significant product emerges [60] Question: Timeline for MTAs to become formal partnerships - The timeline for MTAs to evolve into formal partnerships depends on the partners' development progress, with ongoing discussions and data generation [70][72]

Financial Data and Key Metrics Changes - The company reported total revenue of $1.1 billion for the full year 2025, a 65% increase year-over-year, including $625 million from non-cash revenue recognition related to Nuvaxovid agreements [33][34] - For Q4 2025, total revenue was $147 million, reflecting a 67% increase compared to Q4 2024 [34][38] - The company achieved positive income for both the full year and Q4 of 2025, indicating improved financial performance [34][40] - Cash and accounts receivables at year-end 2025 totaled $857 million, with an additional $80 million in non-dilutive cash expected in Q1 2026 [35][36] Business Line Data and Key Metrics Changes - Nuvaxovid product sales for Q4 2025 were $20 million, with additional supply sales of $19 million from Matrix-M adjuvant sales [38] - Sanofi licensing, royalty, and other revenue for Q4 2025 was $98 million, primarily driven by milestone achievements [38] Market Data and Key Metrics Changes - The company noted a 12% market share for Nuvaxovid in Japan, with over 30 million doses of the R21/Matrix-M malaria vaccine distributed [10] - The global vaccine market is projected to exceed $60 billion in the next four to five years, with the immunotherapeutic vaccines subset in oncology expected to reach over $42 billion by 2032 [23] Company Strategy and Development Direction - The company has shifted from a COVID-focused organization to one that emphasizes long-term value through partnerships and R&D, supported by a lean operating model [8][9] - The partnership with Pfizer for Matrix-M is expected to generate significant revenue through milestones and royalties [9][10] - The company aims to leverage its Matrix technology to create a portfolio of adjuvants, expanding its utility beyond infectious diseases [12][30] Management's Comments on Operating Environment and Future Outlook - Management acknowledged uncertainties in the current macro and regulatory environment for vaccine companies but remains optimistic about the long-term need for vaccines [15] - The company anticipates continued progress in 2026, including potential new partnership announcements and advancements in R&D efforts [14][41] Other Important Information - The company has significantly reduced R&D and SG&A expenses, achieving a 42% reduction for Q4 2025 and a 53% reduction for the full year [34][39] - The 2028 guidance for combined R&D and SG&A expenses is set at $200 million or below, representing a 50% decrease compared to 2025 [42][44] Q&A Session Summary Question: Update on Sanofi's vaccine business strategy with new CEO - Management expressed confidence in the ongoing partnership with Sanofi, noting that interactions remain positive despite leadership changes [54] Question: Prioritization of early pipeline programs - The company is advancing multiple early-stage programs, including C. diff, VZV, and RSV, with promising preclinical results [57] Question: Potential for co-promotions in partnerships - The company is currently focused on partnerships rather than building a commercial framework but remains open to co-promotions for significant products in the future [63] Question: Timeline for MTAs to evolve into formal partnerships - The timeline for MTAs to become formal partnerships depends on the partners' development progress, with ongoing discussions and data generation to facilitate these transitions [71][75]

Financial Data and Key Metrics Changes - Total revenue for 2025 reached $1.1 billion, a 65% increase year-over-year, including $625 million from non-cash revenue recognition related to Nuvaxovid agreements [32][33] - Fourth quarter revenue was $147 million, a 67% increase compared to the same period in 2024, with positive income reported for both the full year and fourth quarter [33][35] - Combined R&D and SG&A expenses were reduced by 42% and 53% for the fourth quarter and full year 2025, respectively, while maintaining partnership commitments [33][38] Business Line Data and Key Metrics Changes - Nuvaxovid product sales for the fourth quarter were $20 million, with additional supply sales of $19 million from Matrix-M adjuvant sales [37] - Sanofi's licensing, royalty, and other revenue amounted to $98 million, driven by milestone achievements and R&D reimbursements [37] Market Data and Key Metrics Changes - Takeda achieved over 12% market share for Nuvaxovid in Japan, and more than 30 million doses of the R21 Matrix-M malaria vaccine were distributed [9] - The global vaccine market is projected to exceed $60 billion in the next four to five years, with the immunotherapeutic vaccines subset in oncology expected to reach over $42 billion by 2032 [21][22] Company Strategy and Development Direction - The company has transitioned from a COVID-focused organization to one that emphasizes partnerships and R&D, aiming for long-term value creation through its Matrix technology [6][8] - The growth strategy includes leveraging R&D to expand the utility of Matrix technology beyond infectious diseases and developing new assets for partnerships [10][11] Management's Comments on Operating Environment and Future Outlook - The management acknowledges significant uncertainties in the current macro and regulatory environment for vaccine companies but remains optimistic about the long-term need for vaccines [13] - The company anticipates continued progress in 2026, including potential new partnership announcements and advancements in its R&D pipeline [12][13] Other Important Information - The company ended 2025 with $857 million in cash and accounts receivables, with an additional $80 million in non-dilutive cash expected in early 2026 [34] - A new credit facility of $330 million was established to provide flexibility and access to non-dilutive capital [34] Q&A Session Summary Question: Update on Sanofi's vaccine business with new CEO - Management expressed confidence in the ongoing partnership with Sanofi, noting that interactions remain positive despite the leadership change [51][52] Question: Prioritization of early pipeline programs - The company is advancing multiple early-stage programs, including C. diff, shingles, and RSV, with no specific prioritization disclosed [54] Question: Interest in co-promotions for Matrix-M - The company is currently focused on partnerships rather than building a commercial framework but remains open to co-promotions if a significant opportunity arises [60] Question: Timeline for MTAs to become formal partnerships - The timeline for MTAs to evolve into formal partnerships depends on the partners' development progress, with ongoing discussions and data generation to facilitate these transitions [72][73]

Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights February 26, 2026 © 2026 NOVAVAX. All rights reserved This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "may," "will," "believe," "estimate," "forecast," "goal," "project," and other words of similar meaning. These forward-looking statements address various matters including Novavax's corporate st ...

Core Insights - Novavax has raised its adjusted revenue forecast for 2026 to between $230 million and $270 million, up from a previous estimate of $185 million to $205 million, driven by expected milestone payments from vaccine supply and licensing deals [2][5] - The company reported a fourth-quarter profit of $18 million, a significant turnaround from a net loss of $81 million in the same quarter the previous year, aided by cost cuts and licensing agreements [2][6] - Novavax anticipates reaching profitability by 2028, supported by key product launches, including a COVID-flu combination vaccine developed in partnership with Sanofi [4][5] Revenue and Financial Performance - Fourth-quarter revenue increased by 67% to $147 million, surpassing analysts' expectations of $78.84 million [5] - The adjusted revenue forecast for 2026 reflects a positive outlook despite challenges from declining demand for COVID-19 vaccines [2][3] Strategic Partnerships and Developments - Novavax has licensed its Matrix-M adjuvant technology to Pfizer for up to $530 million, indicating strong interest in its technology [5] - The company is navigating a changing regulatory landscape and has expressed optimism about future vaccine approvals, as seen with the recent developments regarding Moderna's flu vaccine [3][4]